|
|
C-5
propyne derivatives and G-Clamp
Substitution of C-5 propynyl-dC (pdC) for dC and C-5 propynyl-dU (pdU) for dT are effective strategies to enhance base pairing. Using these base substitutions, duplex stability and melting temperatures are raised by the following amounts: C-5 propynyl-C 2.8° per substitution; C-5 propynyl-U 1.7° per substitution. AP-dC (G-clamp) substitutes for dC and is another very important modified nucleoside that enhances hybridization by 7.5° per substitution. The ability of these modified bases to enhance binding while maintaining specificity has proven useful in antisense research and in the synthesis of high affinity probes. AP-dC is also a fluorescent nucleoside and should find uses in DNA structural research.
| 10-1014-90 |
100 µmole |
85.00 |
| |
10-1014-02 |
0.25g |
245.00 |
| |
10-1014-05 |
0.5g |
490.00 |
| 10-1054-90 |
100 µmole |
65.00 |
| |
10-1054-02 |
0.25g |
195.00 |
| |
10-1054-05 |
0.5g |
390.00 |
| 10-1097-95 |
50 µmole |
230.00 |
| |
10-1097-90 |
100 µmole |
460.00 |
| |
10-1097-02 |
0.25g |
1175.00 |
|
INTELLECTUAL PROPERTY
C-5 Propyne Phosphoramidite AND AP-dC-CE Phosphoramidite
(G-Clamp)
C-5 Propyne and AP-dC Phosphoramidites
This product is covered by patents or patents pending owned by Isis Pharmaceuticals, Inc. (“Isis”). Purchase of this product includes a limited license to use this product solely for internal research. This license specifically excludes (and you have no right to use this product for): (a) therapeutic or diagnostic applications (including products or services that incorporate this product), (b) any in vivo toxicity/safety study in support of an investigational new drug application (or foreign counterpart), (c) resale (including sale of any products or services that incorporate this product) or (d) gene functionalization activities (including products or services that incorporate data derived from gene functionalization activities) if such activities have commercial application, any and all of which require a separate license from Isis. Neither this product nor any product created through its use may be used in human clinical trials.
A simple agreement must be signed before end-users and custom oligo services may purchase these products for use as defined above.
http://www.glenresearch.com/ Reference/PropyneFax.pdf
OTHER INSTRUMENT TYPES
All minor bases, RNA products and modifiers are packaged in septum-capped vials suitable for ABI and other instruments. If you would like another type of vial/column add the following to the end of the catalog number.
Expedite |
E |
Beckman Oligo 1000 |
B |
Pharmacia Gene Assembler |
P |
Mermade |
M |
Applied Biosystems 3900 |
A |
Expedite |
E |
Mermade |
M |
|
Please inquire for availability
of columns for other
instrument types.
|
SEE ALSO
N6-Me-dA
|
bases affecting
duplex stability
C-5 methyl pyrimidine nucleosides are known to stabilize
duplexes relative to the non-methylated bases. Therefore, enhanced binding
can be achieved using 5-methyl-dC in place of dC, duplex melting temperature
being increased by 1.3°. Improved stacking in this case is believed to
be brought about by elimination of water molecules from the duplex. 2,6-Diaminopurine
2'-deoxyriboside (2-amino-dA) forms an additional hydrogen bond with Thymidine,
thereby leading to duplex stabilization with a melting temperature increase
of 3°. Our 2-amino-dA monomer exhibits fast and effective deprotection
in ammonium hydroxide and it is stabilized to depurination during synthesis.
Sequences with high GC content may contain mismatches and still hybridize
because of the high stability of the G-C base pair. The N4-ethyl analogue
of dC (N4-Et-dC) hybridizes specifically to natural dG but the stability
of the base pair is reduced to about the level of an AT base pair.
AP-dC (G-clamp) enhances oligo hybridization since the AP-C....G base pair contains 4 hydrogen bonds, which makes the interaction much stronger than the regular C....G base pair with its 3 hydrogen bonds.
| 10-1060-90 |
100 µmole |
50.00 |
| |
10-1060-02 |
0.25g |
120.00 |
| 20-2060-01 |
0.1g |
50.00 |
| 1 µmole columns |
20-2160-41 |
Pack of 4 |
200.00 |
| 0.2 µmole columns |
20-2160-42 |
Pack of 4 |
120.00 |
| 10-1085-95 |
50 µmole |
70.00 |
| (2,6-diaminopurine) |
10-1085-90 |
100 µmole |
125.00 |
| |
10-1085-02 |
0.25g |
250.00 |
Sequences with high GC content may contain mismatches and still hybridize because of the high stability of the G-C base pair. The N4-ethyl analogue of dC (N4-Et-dC) hybridizes specifically to natural dG but the stability of the base pair is reduced to about the level of an AT base pair.
Coupling N6-Me-dA (10-1003) and N4-Et-dC (10-1068) with 1H-tetrazole leads to a trace of branching at the secondary amine positions, while DCI leads to around 15% branching. In collaboration with Berry and Associates, the acetyl protected monomers were prepared. Acetyl protection was chosen since it would block branching reactions. Oligonucleotides synthesized using these monomers proved to be compatible with all popular deprotection strategies from UltraMild to UltraFast. When the acetyl protected monomers were compared with the unprotected monomers using DCI as activator, branching was reduced from 15% to zero.
| 10-1068-95 |
50 µmole |
125.00 |
| |
10-1068-90 |
100 µmole |
225.00 |
| |
10-1068-02 |
0.25g |
675.00 |
| 10-1513-95 |
50 µmole |
125.00 |
| |
10-1513-90 |
100 µmole |
225.00 |
| |
10-1513-02 |
0.25g |
675.00 |
| 10-1003-90 |
100 µmole |
162.50 |
| |
10-1003-02 |
0.25g |
495.00 |
| 10-1503-90 |
100 µmole |
162.50 |
| |
10-1503-02 |
0.25g |
495.00 |
|
Zip Nucleic Acids (ZNA®)
Spermine phosphoramidite is used to produce oligospermine-oligonucleotide conjugates - Zip Nucleic Acids (ZNA®) Oligos. The name reflects the presumed mode of action. The conjugates are believed to use the oligospermine to seek out and move along (scan) oligonucleotide strands until the probe complementary sequence is located. The oligospermine then performs the function of stabilizing the formed duplex by reducing electrostatic repulsion, thereby leading to significantly increased binding affinities. ZNA® Oligos have found use in the following applications: Multiplex PCR; PCR of AT-rich Regions; RT qPCR; Detection of MicroRNA; Improved SNP Discrimination; and Antisense and Antigene Effects. Spermine phosphoramidite is simple to use in oligonucleotide synthesis and can be added multiple times at the 3’ or 5’ terminus. Deprotection and isolation are also straightforward. HPLC analysis of the conjugates requires high pH to suppress the ionization of the spermine residues.
| 10-1939-95 | 50 µmole | 145.00 |
| 10-1939-90 | 100 µmole | 270.00 |
| 10-1939-02 | 0.25g | 525.00 |
| INTELLECTUAL PROPERTY
“Spermine phosphoramidite” synthon is the subject matter of U.S. Patent Application No. 12/086.599, European Patent Application No. EP20060847298 and foreign equivalents for which Polyplus-transfection is the co-owner. Product is sold for research purposes only. Product shall not be used to manufacture oligospermine-oligonucleotide conjugates for use in diagnostics, clinical or commercial applications including use in humans. There is no implied license to manufacture oligospermine-oligonucleotide conjugates for diagnostic, clinical or commercial applications, including but not limited to contract research. Please contact Polyplus-transfection at licensing@polyplus-transfection.com to obtain a license for such use.
Spermine phosphoramidite is covered under the intellectual property of Polyplus-transfection SA. ZNA® is a registered trademark of Polyplus-transfection SA. |
Locked Nucleic Acid
(LNA™) Phosphoramidites
Locked Nucleic Acid (LNA) phosphoramidites have been discontinued. |
|
Caps for Increased
Duplex Stability and Base-Pairing Fidelity at Termini
New cap structures allow for the preparation of hybridization probes with increased affinity for complementary sequences. The monomers used to prepare capped oligonucleotides are phosphoramidites that can be readily introduced via automated DNA synthesis at the end of solid phase syntheses. The caps favor the formation of stable Watson-Crick duplexes by stacking on the terminal base pair (Figures 1 and 2).
|
|
FIGURE 1: STACKING OF CAP ON TERMINAL BASE PAIR |
FIGURE 2: STACKING OF Uaq CAP ON 3' TERMINAL BASE PAIR |
Melting point increases of over 10 °C per modification can be realized for short duplexes.1,2 The caps fit canonical Watson-Crick base pairs and do not stack well on mismatched base pairs. This leads to increased base pairing selectivity at the terminal and the penultimate position of oligonucleotides featuring the caps. Base pairing fidelity is usually low at the termini, where fraying occurs frequently in the absence of caps. The beneficial effects of the caps are also realized when longer target strands are bound, so there is no need for blunt ends for the duplexes formed.1,2 The caps, when attached to the 5’ terminus of an oligonucleotide, also facilitate purification as their lipophilicity leads to prolonged retention on reversed phase columns or cartridges. Finally, capping of termini may discourage the degradation of oligonucleotides by exonucleases.
3’-Uaq Cap CPG, a Uridine support modified with a 2’- anthraquinone residue, is the most effective oligonucleotide cap known to date.3,4 For short hybrid duplexes between DNA probes and RNA target strands, the increase in ™ is up to 18 °C and the modification is effective in increasing the ™ of DNA:DNA, RNA:RNA, and DNA:RNA hybrid duplexes. 3’-Uaq Cap also increases probe specificity by depressing the melting point of terminal mismatches.
| 10-1986-90 |
100 µmole |
195.00 |
| |
10-1986-02 |
0.25g |
495.00 |
| 10-1987-90 |
100 µmole |
195.00 |
| |
10-1987-02 |
0.25g |
495.00 |
| 20-2980-01 | 0.1g | 180.00 |
| | 20-2980-10 | 1.0g | 1500.00 |
| 1 µmole columns | 20-2980-41 | Pack of 4 | 300.00 |
| 0.2 µmole columns | 20-2980-42 | Pack of 4 | 150.00 |
| 10 µmole column (ABI) | 20-2980-13 | Pack of 1 | 750.00 |
| 15 µmole column (Expedite) | 20-2980-14 | Pack of 1 | 1125.00 |
|
References
(1) Dogan, Z.; Paulini, R.; Rojas Stütz, J. A.;
Narayanan, S.; Richert, C. J. Am. Chem. Soc. 2004, 126, 4762-4763.
(2) Narayanan, S.; Gall, J.; Richert, C. Nucleic Acids Res. 2004, 32,
2901-2911.
(3) A. Patra, C. Richert, J. Amer. Chem. Soc., 2009, 131, 12671-12681.
(4) C. Ahlborn, K. Siegmund, C. Richert, J. Amer. Chem. Soc., 2007, 129, 15218-15232.
|
http://www.glenres.com/Catalog/duplex.html
|
|